Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibα glycoprotein

British Journal of Pharmacology

Volumn 154, Issue 6, 2008, Pages 1216-1224

  Ferreira, M A D ^a   Do Nascimento, N R F ^b   De Sousa, C M ^b   Pessoa, O D L ^a   De Lemos, T L G ^a   Ventura, J S ^c   Schattner, M ^d   Chudzinski Tavassi, A M ^c  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b STATE UNIVERSITY OF CEARÁ   (Brazil)

^c INSTITUTO BUTANTAN   (Brazil)

^d ACADEMIA NACIONAL DE MEDICINA   (Argentina)

Author keywords

Antiplatelet activity; Auxemma oncocalyx; Human platelets; Oncocalyxone; Quinones

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; CYCLIC AMP; CYCLIC GMP; FIBRINOGEN; GLYCOPROTEIN IB ALPHA; NITRIC OXIDE; NITROPRUSSIDE SODIUM; ONCOCALYXONE A; PADGEM PROTEIN; PLANT EXTRACT; RISTOCETIN; SILDENAFIL; THROMBIN; VON WILLEBRAND FACTOR;

ADULT; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG PROTEIN BINDING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; MALE; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; TURBIDIMETRY;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; ANTHRAQUINONES; BLOOD PLATELETS; CYCLIC AMP; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 5; FEMALE; FLOW CYTOMETRY; GUANYLATE CYCLASE; HUMANS; MALE; MIDDLE AGED; NITRIC OXIDE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; PROTEIN BINDING; THROMBOXANE A2;

EID: 47249091288     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.199     Document Type: Article

References (50)

1. Born GVR, Cross MJ (1963). The aggregation of blood platelets. J Physiol 168: 178-195.
2. Brown PC, Dulik DM, Jones TW (1991). The toxicity of menadione (2-methyl-1,4-naphthoquinone) and two thioether conjugates studied with isolated renal epithelial cells. Arch Biochem Biophys 285: 187-196.
3. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T et al. (2006). High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost 4: 542-549.
4. DeLuca M, McElory WD (1978). Purification and properties of firefly luciferase. Methods Enzymol 57: 3-15.
5. 2+ homeostasis. Arch Biochem Biophys 235: 343-350.
6. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S (2002). Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105: 1650-1655.
7. Ferreira MAD, Leal LKAM, Pessoa ODL, Lemos TLG, Barros SBM, Viana GSB (2001). Antioxidant activity of Quinones isolated from Auxemma oncocalyx Taub. In: VI Pharmatech, Recife, Brazilian Pharmacy Meeting, pp 183-184.
8. Ferreira MAD, Nunes ODRH, Fujimura AHY, Pessoa ODL, Lemos TLG, Viana GSB (1999). Inhibition of platelet activation by quinones isolated from Auxemma oncocalyx Taub. Res Commun Mol Pathol Pharmacol 106: 97-107.
9. Ferreira MAD, Nunes ODRH, Fontenele JB, Pessoa ODL, Lemos TLG, Viana GSB (2004). Analgesic and anti-inflammatory activities of a fraction rich in oncocalyxone A isolated from Auxemma oncocalyx. Phytomedicine 11: 315-322.
10. Ferreira MAD, Nunes ODRH, Leal LKAM, Pessoa ODL, Lemos TLG, Viana GSB (2003). Antioxidant effects in the quinone fraction from Auxemma oncocalyx Taub. Biol Pharm Bull 26: 595-599.
11. Galle J, Zabel U, Hübner U, Hatzelmann A, Wagner B, Wanner C et al. (1999). Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127: 195-203.
12. Geiger J (2001). Inhibitors of platelet signal transduction as antiaggregatory drugs. Expert Opin Investig Drugs 10: 865-890. Review.
13. Guh JH, Ko FN, Jong TT, Teng CM (1995). Antiplatelet effect of gingerol isolated from Zingiber officinale. J Pharm Pharmacol 97: 329-332.
14. Gum PA, Kottke-Marchant K, Poggio ED, Gurm H, Welsh PA, Brooks L et al. (2001). Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88: 230-235.
15. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ (2003). A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 41: 961-965.
16. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM (2003). Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107: 2908-2913.
17. Haslam RJ, Dickinson NT, Jang EK (1999). Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost 82: 412-423.
18. Hass WK, Easton JD, Adams Jr HP, Pryse-Phillips W, Molony BA, Anderson S et al. (1989). A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 321: 501-507.
19. Herman AG (1998). Rationale for the combination of anti-aggregating drugs. Thromb Res 92: S17-S21.
20. Jackson SP, Nesbitt WS, Kulkarni S (2003). Signaling events urderlying thrombus formation. J Thromb Haemost 1: 1602-1612.
21. 2+ mobilization. J Pharmacol Exp Ther 312: 214-219.
22. Kim SR, Lee JY, Lee MY, Chung SM, Bae ON, Chung JH (2001). Association of quinone-induced platelet anti-aggregation with cytotoxicity. Toxicol Sci 62: 176-182.
23. Ko FN, Lee YS, Kuo SC, Chang YS, Teng CM (1995). Inhibition on platelet activation by shikonin derivatives isolated from Arnebia euchrona. Biochem Biophis Acta 1268: 329-334.
24. Ko FN, Wu CC, Kuo SC, Lee FY, Teng CM (1994). YC-1 a novel activator of platelet guanylate cyclase. Blood 84: 4226-4233.
25. Law MR, Wald NJ (2003). Environmental tobacco smoke and ischemic heart disease. Prog Cardiovasc Dis 46: 31-38. Review.
26. Leone A (2005). Biochemical markers of cardiovascular damage from tobacco smoke. Curr Pharm Des 11: 2199-2208. Review.
27. Leyva A, Pessoa C, Boogaerdt F, Sokaroski R, Lemos TL, Wetmore LA et al. (2000). Oncocalyxones A and C, 1,4-anthracenediones from Auxemma oncocalyx: comparison with anticancer 1,9-antracendiones. Anticancer Res 20: 1029-1031.
28. Lotufo LVC, Ferreira MAD, Lemos TLG, Pessoa ODL, Viana GSB, Cunha GMA (2002). Toxicity to sea urchin egg development of the quinone fraction obtained from Auxemma oncocalyx. Braz J Med Biol Res 35: 927-930.
29. Marques WB, Dos Santos HS, Pessoa OD, Braz-Filho R, Lemos TL (2000). Anthracene derivatives from Auxemma oncocalyx. Phytochemistry 55: 793-797.
30. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I et al. (2004). Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 109: 3171-3175.
31. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM et al. (1996). cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci 93: 1480-1485.
32. Mullershausen F, Russwurm M, Friebe A, Koesling D (2004). Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109: 1711-1713.
33. Pessoa C, Silveira ER, Lemos TL, Wetmore LA, Moraes MO, Leyva A (2000). Antiproliferative effects of compounds derived from plants of northeast Brazil. Phytother Res 14: 187-191.
34. Pessoa C, Vieira FM, Lemos TG, Moraes MO, Lima PD, Rabenhorst SH et al. (2003). Oncocalixona A from Auxemma oncocalyx lacks genotoxic activity in phytohemagglutinin-stimulated lymphocytes. Teratog Carcinog Mutagen Suppl 1: 215-220.
35. Pessoa ODL, De Lemos TLG, De Carvalho MG, Braz-Filho R (1995). Cordiachoromes from Auxemma oncocalyx. Phytochemistry 40: 1777-1786.
36. Pessoa ODL, De Lemos TLG, Silveira ER, Braz-Filho R (1993). Novel cordiachromes isolated from Auxemma oncocalyx. Nat Prod Lett 2: 145-150.
37. Reis ALA, Ormelli CB, Miranda ALP, Fraga CAM, Barreiro EJ (1999). Studies on antiplatelet agents from natural safrole. II. Synthesis and pharmacological properties of novel functionalized oxime O-benziylether derivatives. Pharmaceutica Acta Helvetiae 74: 19-28.
38. Ruggeri ZM (2002). Platelets in atherothrombosis. Nat Med 8: 1227-1234. Review.
39. Schwarz UR, Walter U, Eigenthaler M (2001). Taming platelets with cyclic nucleotides. Biochem Pharmacol 62: 1153-1161.
40. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ (2005). Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 45: 246-251.
41. Sheu JR, Kan YC, Hung WC, Lin CH, Yen MH (2000). The antiplatelet activity of tetramethylpyrazine is mediated through activation of NO synthase. Life Sciences 67: 937-947.
42. Siess W (1989). Molecular mechanisms of platelet activation. Physiol Rev 69: 58-178.
43. Sousa CM, Nascimento NRF, Lemos TLG, Pessoa ODL, Ferreira MAD (2002). Evaluation of the platelet antiaggregant and vasopressor activity of oncocalyxone A (OncoA) isolated from the quinone fraction of Auxemma oncocalyx Taub. In: XXXIV Brazilian Meeting of the Pharmacology and Experimental Therapeutics Society. Brazilian Pharmacology Meeting, Águas de Lindóia, Abstract 01.070, pp 94.
44. Stasch J-P, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A et al. (2001). NO-independent regulatory site on soluble guanylate cyclase. Nature 410: 212-215.
45. Teng CM, Lin CH, Lin CN, Chung MI, Huang TF (1993). Frangulin B, an antagonist of collagen-induced platelet aggregation and adhesion, isolated from Rhamnus formosana. Thromb Haemost 70: 1014-1018.
46. Tzeng WF, Chiou TJ, Wang CP, Lee JL, Chen YH (1994). Cellular thiol as a determinant of responsiveness to menadione in cardiomyocytes. J Mol Cell Cardiol 26: 889-897.
47. Wallis RM, Corbin JD, Francis SH, Ellis P (1999). Tissue distribution of phosphodiesterase families and effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 83: 3C-12C.
48. Ward CM, Andrews RK, Smith AI, Berndt MC (1996). Mocarhagin, a novel cobra venom metalloproteinase, cleaves the platelet von Willebrand factor receptor glycoprotein Iba. Identification of the sulfated tyrosine/anionic sequence Tyr-276-Glu-282 of glycoprotein Ibα as a binding site for von Willebrand factor and α-thrombin. Biochemistry 35: 4929-4938.
49. Wu TS, Tsang ZJ, Wu PL, Lin FW, Li CY, Teng CM et al. (2001). New constituents and antiplatelet aggregation and anti-HIV principles of Artemisia capillaries. Bioorg Med Chem 9: 77-83.
50. 2+ mobilization. Biol Pharm Bull 24: 618-622.